Onconic Therapeutics said on the 1st that it filed an investigational new drug (IND) application with the Ministry of Food and Drug Safety for a Phase 2 clinical trial in Korea of the combination therapy of its next-generation anticancer drug candidate "Nesuparib" and Celltrion's anticancer drug "Vegzelma."
Nesuparib is a next-generation synthetic lethal anticancer drug candidate based on a dual-inhibition mechanism that simultaneously inhibits "PARP," which is responsible for repairing DNA damage in cancer cells, and "tankyrase," which is involved in cancer growth and proliferation.
Vegzelma is an antibody biosimilar (biopharmaceutical replica) that suppresses tumor angiogenesis by blocking vascular endothelial growth factor (VEGF) signaling.
The Phase 2 trial will comprehensively evaluate the safety, tolerability, and antitumor efficacy of the combination therapy of Nesuparib and Vegzelma. An Onconic Therapeutics official said, "Through strategic collaboration with Vegzelma, Nesuparib will create new value as an innovative anticancer drug in the global ovarian cancer market."